Rapid increase in purchasing teams expected at CPHI North America

SaniSure accelerates drug speed to market with Fill4Sure launch

I am writing to you with some exciting news from Sanisure, who has announced the launch of Fill4Sure™, a custom single-use filling assembly designed to expedite drugs to the market. Fill4Sure™ provides a cost-efficient solution to the critical challenges drug manufacturers experience throughout the fill-finish process. It offers tailor-made assemblies and allows for effortless scaling up or down to meet the varying needs across the industry. Here are some key features and benefits of Fill4Sure™: Extremely clean, low-particulate 2D surge bags Silicone over-molding for enhanced durability High-performance tubing for accuracy Oil and adhesive-free OEM and custom-designed needles These features streamline biomanufacturing or bioprocessing processes, helping manufacturers expand their capacity and secure supply chains. For more details, please refer to the full release below. Thanks, Char Winspear

Alfa Chemistry: Enhancing Thin Layer Chromatography (TLC) Capabilities with New Derivatization Reagents

Alfa Chemistry, a reliable chemical supplier, is pleased to announce the addition of a comprehensive range of derivatization reagents for use in Thin Layer Chromatography (TLC). These reagents are specifically designed to enhance the detection and analysis of compounds on TLC plates, enabling researchers to achieve better results in their experiments.

BOC Sciences to Present Its Novel Solutions at the 2024 TIDES USA Conference

BOC Sciences, a globally renowned supplier with over a decade of experience in the biochemical supply chain, is thrilled to announce its participation in this year's TIDES USA or the Oligonucleotide and Peptide Therapeutics conference. The BOC Sciences team will showcase its cutting-edge products and services at booth #937.

VieCure Streamlines Cancer Care by Adding E-Prescribing Solutions from DrFirst

Anatomy IT's HEALTHIT™ Framework Offers Providers Holistic View of IT and Cyber Readiness

ImpediMed to Present Chronic Breast Cancer-related Lymphedema Study Results at American Society of Breast Surgeons Annual Meeting

Qinecsa Host Industry Discussion on Mastering Medical Device Regulations to Integrate Devices into Pharma Portfolios

Qinecsa Solutions (Qinecsa), specialists in technology-led end-to-end pharmacovigilance solutions, will present an in-depth exploration of medical device regulations, for pharmacovigilance professionals seeking mastery in compliance and operational excellence.

UK Biobank and DNAnexus Collaboration Earns Bio-IT World 2024 Innovative Best Practices Global Impact Award for 500,000 Whole Genomes Data Release

DNAnexus announced that its ongoing collaboration with UK Biobank will be recognized with the 2024 Innovative Best Practices Global Impact Award at the upcoming Bio-IT World Conference and Expo.

SPT Labtech Appoints Rob Walton as New Chief Executive Officer

Dotmatics Luma Lab Connect Unlocks the Untapped Value of Lab Instrument Data to Accelerate Scientific R&D Decision-Making

Luma Lab Connect automatically centralizes, parses, and models data from lab instruments and other data sources for deeper analysis and insights on one harmonized, low-code cloud platform.

DNAnexus and Oracle Collaborate to Advance Precision Health

DNAnexus announced a collaboration with Oracle to advance precision health.

ProPharma Announces Changes to Its Executive Leadership Team

ProPharma announces changes to its executive leadership team with strategic appointments to propel global growth

Qinecsa Solutions announces acquisition of Insife to expand its end-to-end pharmacovigilance technology solutions

Qinecsa Solutions (Qinecsa), specialists in technology-led end-to-end pharmacovigilance solutions, proudly announces its acquisition of Insife ApS (Insife), a well-established Danish-based software, technology, and consultancy firm specializing in developing revolutionary pharmacovigilance platforms.

Bios Health Group Unveils Bios Innovation Circle™

Bios Health Group Unveils Bios Innovation Circle™ Groundbreaking venture studio and strategic hub empowers members with comprehensive arsenal of benefits to dominate the life sciences arena

ResultsCX Named ‘Major Player’ in NelsonHall’s NEAT Vendor Evaluation for CX Services Transformation

Emmes Endpoints Solutions Submits Duchenne Video Assessment Qualification Plan to FDA

Bespak confirms completion of inhaled and nasal drug delivery business separation from Recipharm to focus on the transition to low GWP pMDIs

Spin-out unites three sites to create a leading global CDMO as further significant investments announced at Holmes Chapel site

Tome Biosciences Announces US Patent Issued for Integrase-Mediated Programmable Genomic Integration

Tome Biosciences, Inc., the programmable genomic integration (PGI) company, today announces the issuance of US Patent 11,952,571 for “Systems, Methods, and Compositions for Site-Specific Genetic Engineering Using Programmable Addition via Site-Specific Targeting Elements (PASTE)” by the US Patent and Trademark Office. This patent further protects Tome’s foundational PGI technology, integrase-mediated PGI (I-PGI), describes a system capable of performing I-PGI in a mammalian cell, and is exclusively licensed to Tome from MIT.

Model Medicines Unveils Groundbreaking AI Drug Discovery Advances in New Chemistry and New Biology with Two New Preprint Papers

Model Medicines has announced the upcoming release of two groundbreaking preprint papers on bioRxiv, detailing significant advances in antiviral and oncology drug discovery using their GALILEO AI platform. The first preprint reveals the discovery of a novel broad-spectrum antiviral target and inhibitor, while the second introduces ChemPrint, a deep learning model that achieved a remarkable 45.5% hit rate in identifying novel inhibitors of challenging oncology targets. These findings build upon Model Medicines' recent successes and underscore the transformative potential of their AI platform in revolutionizing drug discovery.